Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Turbos has now launched leveraged trading, and users can receive airdrop incentives for trading.

Turbos has now launched leveraged trading, and users can receive airdrop incentives for trading.

Odaily星球日报Odaily星球日报2026/01/23 09:58
Show original

According to official news from Odaily, Turbos has officially launched its leverage trading feature. Users can now experience leverage effects and real returns directly on the Sui network through Turbos' intuitive interface. This feature supports up to 5x leverage, and the initial trading pairs include SUI–USDC, DEEP–USDC, and WAL–USDC.

In addition, users who trade with leverage via https://app.turbos.finance/#/margin have the opportunity to receive a $DEEP airdrop.

With DeepBook's trading infrastructure and Turbos' user-friendly UI/UX, traders can seamlessly manage positions, effectively control risk, and achieve one-stop leveraged trading.

Turbos will continue to launch innovative products in the future, bringing users a more diverse DeFi experience.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%